



INNOVATIVE SCIENCE • REAL VALUE

Suite 105
48 Atchison Street
St Leonards NSW 2065 Australia
ABN 25 001 150 849

Phone: 61 0428 002 590
Email: admin@scidev.com.au
Website: www.scidev.com.au
ASX code: SDV

Companies Announcements
Australian Securities Exchange

13 February 2019

\$2.5million Fund Raising to Accelerate Growth

- **SciDev signs \$2.5 million capital raising mandate with Taylor Collison Ltd to facilitate growth, comprising a placement (\$1.25 million) and non-renounceable Entitlement Offer (\$1.25 million).**
- **Strong synergies between Nuoe transaction and SciDev's patent pending OptiFlox® technology to underpin aggressive growth plans to lift SciDev's revenue profile.**
- **Funding will be used to support roll out of the OptiFlox® technology and execute combined Nuoe/SciDev business development pipeline.**

Further to Monday's announcement by SciDev Ltd (**ASX: SDV, SDV or the Company**) related to the securing of exclusive distribution and marketing rights in Australia and other Oceanic countries for polymer products produced by the China-based Nuoe Group (**Nuoe Group**), SDV is pleased to now outline the terms of a \$2.5 million fund raising initiative to accelerate the Company's business growth.

The fund raising is the subject of a mandate signed with Taylor Collison Ltd and is detailed below.

\$1.25 Million Placement

As announced on 11 February 2019, SciDev has undertaken a \$470,000 capital raising share placement in parallel with the Nuoe transaction (**1st Tranche Placement**). \$300,000 of that capital raising share placement was taken up by the Nuoe Groups' Australian executive Dr Zhang (**Zhang**), who will become an executive Director of SciDev's operating subsidiary Science Developments Pty Ltd (**SDPL**). The balance was taken up by unrelated investors, and SciDev welcomes these new shareholders to the Company and looks forward to working closely with Dr Zhang.

A further \$780,000 capital raising share placement will be carried out by the Company at \$0.06 per share (**2nd Tranche Placement**). This will bring the total new working capital raised by way of placement to \$1.25 million. Issue of the 2nd Tranche Placement shares will be conditional on SciDev shareholder approval of the proposed share issues, as they will exceed the Company's 15% placement capacity.

A SciDev shareholders meeting will be called shortly in order to consider both ratification of the 1st Tranche Placement and approval of the 2nd Tranche Placement.

\$1.25 Million Non-renounceable Entitlement Offer

In parallel with the capital raising share placement referred to above, SciDev will undertake a non-renounceable Entitlement Offer to raise a further \$1.25 million (the **Entitlement Offer**), bringing the total of new working capital raised to \$2.5 million. The Entitlement Offer will be carried out on a 2:7 basis and priced at \$0.06 per new share.

Taylor Collison Ltd has offered to act as underwriter to the Entitlement Offer and an underwriting agreement was signed late yesterday. Taylor Collison Limited will be paid a management fee of 2% of the total Entitlement Offer amount and a 4% Underwriting Fee on the amount underwritten.

Eligible shareholders will be offered 2 new SciDev shares at an issue price of \$0.06 per share for every 7 existing SciDev shares held on the record date (7:00pm AEST on 18 February 2019). Up to 20,947,264 new SciDev shares will be offered under the Entitlement Offer to raise up to approximately \$1.25 million before costs, assuming no existing options are exercised.

The issue price of \$0.06 per new SciDev share represents a discount of approximately 16.7% to the last closing price of SciDev shares on the morning of 4 February 2019 (being the morning of trading prior to the Company entering into a trading halt ahead of this announcement) and a 2.4% discount to the 15-day volume weighted average price up to and including that day.

Shareholders with a registered address in Australia and New Zealand will be eligible to participate in the Entitlement Offer. Shareholders outside of these jurisdictions will not be permitted to participate. It is the current intention of most of the Directors to take up their rights in full.

An indicative timetable for the Entitlement Offer is set out below.

Event	Date*
Cleansing Notice S708AA with ASX	13 February 2019
Announcement of Offer and Letter to Optionholders	13 February 2019
Lodgement of Appendix 3B with ASX	13 February 2019
Letters to Shareholders, Ineligible Shareholders.	14 February 2019
"Ex" Date (date Shares are quoted ex-rights)	15 February 2019
Record Date to determine Entitlements	7.00pm (AEDT) 18 February 2019
Offer Documents (together with Entitlement and Acceptance Form) despatched to Shareholders and announce despatch	21 February 2019

Event	Date*
Latest date to extend offer (at least 3 days prior to Closing date)	5 March 2019
Closing date (this is earliest possible date)	5pm (AEDT) 8 March 2019
Shares quoted on a deferred settlement basis	11 March 2019
Notification to ASX of under subscriptions	13 March 2019
Issue date	15 March 2019
Normal trading of Shares issued under the Offer commences**	18 March 2019

* These dates are indicative only. The Directors (in consultation with the Underwriter) reserve the right to vary the key dates without prior notice, subject to the Listing Rules.

** The Directors (in consultation with the Underwriter) may extend the Closing Date by giving at least three Business Days' notice to ASX prior to the Closing Date. As such, the date the Shares are expected to commence trading on ASX may vary.

The following documents are attached:

- A Cleansing Statement with regard to the 1st Tranche Placement.
- A Cleansing Statement with regard to the Entitlement Offer.
- An Appendix 3B with regard to the Entitlement Offer.
- Pro-Forma Letter to SciDev Optionholders.

Heath Roberts
Company Secretary
SciDev Ltd
0419 473925



INNOVATIVE SCIENCE • REAL VALUE

Suite 105
48 Atchison Street
St Leonards NSW 2065 Australia
ABN 25 001 150 849

Phone: 61 0428 002 590
Email: admin@scidev.com.au
Website: www.scidev.com.au
ASX code: SDV

13 February 2019

Companies Announcements
Australian Securities Exchange

Dear Sirs,

SciDev Ltd – Cleansing Notice

SciDev Ltd (ASX:SDV, **SciDev** or the **Company**) refers to the issue of 9,500,000 fully paid ordinary shares (refer Appendix 3B released 11 February 2019) and issues this cleansing notice.

Cleansing Notice

In relation to the issue of shares referred to herein and the Appendix 3B Notice released on Monday, 11 February 2019, the Company gives notice under section 708A (5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) that:

1. It issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice, the Company has complied with:
 - a) The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b) Section 674 of the Corporations Act; and
3. As at the date of this notice, there is no excluded information (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) which is required to be set out in this notice under Section 708A (6) (e) of the Corporations Act.

Yours Sincerely
SciDev Ltd

Heath Roberts
Company Secretary



INNOVATIVE SCIENCE • REAL VALUE

Suite 105
48 Atchison Street
St Leonards NSW 2065 Australia
ABN 25 001 150 849

Phone: 61 0428 002 590
Email: admin@scidev.com.au
Website: www.scidev.com.au
ASX code: SDV

13 February 2019

Companies Announcements
Australian Securities Exchange

Dear Sirs,

SciDev Limited ABN 25 001 150 849 (ASX:SDV) Entitlement Issue Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001

This Notice is given by SciDev Ltd (ASX:SDV, **SciDev** or the **Company**) under Section 708AA(2)(f) of the Corporations Act 2001 (Cth) (the **Act**) as notionally modified by ASIC Class Order 08/35.

SciDev today announced a pro-rata non-renounceable entitlement issue (**Entitlement Issue**) of two (2) fully paid ordinary shares (**New Shares**) for every seven (7) ordinary shares held as at 7.00pm (Sydney Time) on 18 February 2019 by SciDev's eligible shareholders. The issue price for each New Share under the Entitlement Issue will be \$0.06.

SciDev advises that:

- (a) the New Shares will be offered for issue without disclosure under Part 6D.2 of the Act;
- (b) this notice is being given under Section 708AA(2)(f) of the Act;
- (c) as at the date of this notice SciDev has complied with:
 - i. the provisions of Chapter 2M of the Act as they apply to SciDev; and
 - ii. Section 674 of the Act;
- (d) as at the date of this notice there is no excluded information of the type referred to in sub-sections 708AA(8) or (9) of the Act; and
- (e) the potential effect the Entitlement Issue will have on the control of SciDev, and the consequences of that effect, will depend on a number of factors, including shareholder demand. The potential effect and the consequences of that effect are assessed further below.

SciDev will use the funds for working capital and to grow the domestic and international footprint of its business. The Company has on issue 73,315,421 ordinary shares, and 3,950,000 options. The Company does not anticipate that any of options will be exercised in order to take advantage of the Entitlement Issue.

Taylor Collison Ltd (**TCL**) is acting as Lead Manager and Underwriter to the Entitlement Issue.

The issue of New Shares under the Entitlement Issue is not expected to have any material effect or consequence on the control of SciDev, however is dependent on a number of factors including investor demand. Therefore, it is not possible to predict the effect of the Entitlement Issue on the control of SciDev. There are a number of


possible outcomes that may arise which will, largely, depend on the extent to which eligible shareholders take up their entitlements.

If all eligible shareholders take up their entitlement, each eligible shareholder's ownership interest (and voting power) in SciDev will remain largely unchanged and the effect on the control of SciDev will be negligible.

To the extent that any eligible shareholder fails to take up their Entitlement, that eligible shareholder's percentage holdings in SciDev will be diluted by those other eligible shareholders who take up some or all of their entitlement. The voting power of in-eligible foreign shareholders will be diluted.

If no eligible shareholders take up their entitlements (which SciDev considers extremely unlikely) or some shareholders do not take up their entitlements, then the underwriter will be required to subscribe the shortfall shares. In these circumstances, the Company will ensure that the maximum possible voting power of TCL or anyone acquiring shortfall shares will be limited to 19.99 %. However, as TCL's obligations will arise post the Entitlement Issue the board of SciDev considers that the Entitlement Issue and the underwriting thereof is unlikely to materially affect the control of SciDev.

Yours Sincerely
SciDev Ltd



Heath Roberts
Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

SciDev Ltd (ASX:SDV)

ABN

25 001 150 849

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|---|
| 1 | +Class of +securities issued or to be issued | Fully paid ordinary (ASX:CGN) |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | Approximately 20,947,264 fully paid ordinary shares to be issued through a 2 for 7 pro-rata non-renounceable Entitlement Offer. |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares ranking equally with all other fully paid ordinary shares. |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B
New issue announcement

4	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Yes</p>
5	<p>Issue price or consideration</p>	<p>\$0.06</p>
6	<p>Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>The proceeds of the Entitlement Offer will be used for working capital and for growing the domestic and international footprint of the business of the Company</p>
6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>No</p>
6b	<p>The date the security holder resolution under rule 7.1A was passed</p>	<p>N/A</p>
6c	<p>Number of +securities issued without security holder approval under rule 7.1</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

For personal use only

For personal use only

6d	Number of +securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of +securities issued under an exception in rule 7.2	N/A	
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	<p>+Issue dates</p> <p><small>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</small></p> <p><small>Cross reference: item 33 of Appendix 3B.</small></p>	15 March 2019	
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number	+Class
		94,262,685	Fully Paid Ordinary Shares.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

	Number	+Class
9	3,950,000	Options at \$0.25 per share expiring 28/11/2019
10	N/A	

Part 2 - Pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-Renounceable Entitlement Offer
13	Ratio in which the +securities will be offered	2 New Shares for Every 7 Existing Share
14	+Class of +securities to which the offer relates	Fully paid ordinary shares
15	+Record date to determine entitlements	7.00pm (EST) 18 February 2019
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Entitlements are rounded up.
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	All countries other than Aust and NZ

+ See chapter 19 for defined terms.

For personal use only

19 Closing date for receipt of
acceptances or renunciations

For personal use only

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

20	Names of any underwriters	Taylor Collison Ltd
21	Amount of any underwriting fee or commission	Gross 6%
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	21 February 2019
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	13 February 2019. Small number of Director and staff options only.
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

+ See chapter 19 for defined terms.

For personal use only

32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	+Issue date	Est 15 March 2019

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities
(tick one)

(a) +Securities described in Part 1

(b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B
New issue announcement

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought	N/A							
39	+Class of +securities for which quotation is sought	N/A							
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	N/A							
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>	N/A							
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	<table border="1"> <thead> <tr> <th data-bbox="726 1552 1029 1601">Number</th> <th data-bbox="1029 1552 1316 1601">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="726 1601 1029 1823">N/A</td> <td data-bbox="1029 1601 1316 1823">N/A</td> </tr> </tbody> </table>	Number	+Class	N/A	N/A	<table border="1"> <thead> <tr> <th data-bbox="1029 1552 1316 1601">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="1029 1601 1316 1823">N/A</td> </tr> </tbody> </table>	+Class	N/A
Number	+Class								
N/A	N/A								
+Class									
N/A									

+ See chapter 19 for defined terms.

For personal use only

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date: 13 February 2019.
(Director/Company secretary)

Print name: Heath Roberts.....

== == == == ==

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	49,481,867
Add the following: <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	14,333,554 fully paid ordinary shares
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	
“A”	63,815,421

+ See chapter 19 for defined terms.

For personal use only

Step 2: Calculate 15% of "A"	
"B"	0.15 <i>[Note: this value cannot be changed]</i>
Multiply "A" by 0.15	9,572,313
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	9,500,000
"C"	-
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	9,572,313
<i>Note: number must be same as shown in Step 2</i>	
Subtract "C"	9,500,000
<i>Note: number must be same as shown in Step 3</i>	
Total ["A" x 0.15] – "C"	72,313
	<i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

For personal use only

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p>Notes:</p> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
“E”	

+ See chapter 19 for defined terms.

For personal use only

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
<p>"A" x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	
<p>Subtract "E"</p> <p><i>Note: number must be same as shown in Step 3</i></p>	
<p>Total ["A" x 0.10] – "E"</p>	<p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

For personal use only

+ See chapter 19 for defined terms.



INNOVATIVE SCIENCE • REAL VALUE

Suite 105
48 Atchison Street
St Leonards NSW 2065 Australia
ABN 25 001 150 849

Phone: 61 0428 002 590
Email: admin@scidev.com.au
Website: www.scidev.com.au
ASX code: SDV

13 February 2019

Dear SciDev Optionholder,

Participation in SciDev Entitlements Issue


SciDev Ltd (**SciDev** or the **Company**) announced on 13 February 2019 that it will undertake a non-renounceable Entitlements Issue of 2 shares for every 7 shares held at A\$0.06 (6 cents) per share to raise approximately 1.25 million before costs. That offer is only being extended to holders of ordinary shares with a registered address in Australia and New Zealand, as at 7.00pm AEDT on the record date of 18 February 2019. A copy of the Company's announcement which contains details of the Entitlements Issue is attached.

This notice is sent to you as a holder of options to acquire ordinary shares in SciDev.

Your options do not carry a right to participate in the Entitlements Issue. The purpose of this letter is to give you notice of the Entitlements Issue and to give you the opportunity to exercise any of your options should you wish to participate in the Entitlements Issue in respect of the shares that would be issued to you upon exercise of any of your options (assuming that you have a registered address in Australia or New Zealand).

You would need to exercise the options prior to 7.00pm AEDT 18 February 2019 to allow the underlying shares to be issued to you before 7.00pm AEDT on the Entitlements Issue record date of 18 February 2019. Before deciding whether to exercise any options you hold prior to the record date and participate in the Entitlements Issue you should consider the terms of the Entitlements Issue carefully and, if in doubt, you should consult your stockbroker, accountant or other professional adviser.

Yours Sincerely
SciDev Ltd



Heath Roberts
Company Secretary